drugset / Trial / NCT04701918
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
Timeline
- Start
- 2021-06-04
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |